retatrutide efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 What is Retatrutide treatment: Boost
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30











:max_bytes(150000):strip_icc()/VWH-GettyImages-1793641166-3555361b354b4d0292bdb0cd34c6f241.jpg)













